Valuation: Cardiol Therapeutics Inc.

Market Cap 186M 132M 118M 110M 99.25M 12.61B 189M 1.32B 522M 6.59B 497M 487M 20.88B P/E 2026 *
-3.31x
P/E 2027 * -5.42x
Enterprise Value 167M 119M 106M 98.37M 89.07M 11.31B 169M 1.18B 468M 5.92B 446M 437M 18.73B EV / Sales 2026 *
-
EV / Sales 2027 * 107x
Free-Float
97.73%
Yield 2026 *
-
Yield 2027 * -
23/09 Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead of Schedule and Expands Pivotal Trial CI
23/09 Cardiol Therapeutics Inc. Achieves MAVERIC Enrollment Target And Expands Pivotal Trial Evaluating CardiolRx CI
13/08 Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
12/05 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/05 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
07/05 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
07/05 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
07/05 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
28/04 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
28/04 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
02/04 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
01/04 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
01/04 Cardiol Therapeutics Inc. Provides Update on Strategic Priorities CI
1 week+1.27%
Current month-32.91%
1 month-33.47%
3 months-3.05%
6 months-16.75%
Current year+21.37%
1 week 1.54
Extreme 1.54
1.67
1 month 1.53
Extreme 1.53
2.42
Current year 1.22
Extreme 1.225
3.23
1 year 1.22
Extreme 1.225
3.23
3 years 1.02
Extreme 1.02
4.26
5 years 0.61
Extreme 0.61
5.35
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 19/01/2017
Director of Finance/CFO - 16/08/2018
Chief Operating Officer - 03/12/2020
Director TitleAgeSince
Director/Board Member - 15/12/2017
Director/Board Member - 19/01/2017
Chairman - 07/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/26 Option

Chairman

25,000 0.0214%
8/9/26 Option

Chairman

-25,000 0.0214%
28/8/26 Option

Chief Technology Officer

-70,000 0.0599%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.27%-6.47%+44.55% 133M
+0.88%+1.18%+40.64%+74.91% 64.69B
-0.26%+6.91%+9.79%+77.36% 54.78B
+0.47%+3.52%+9.71%+100.95% 53.49B
-1.47%+3.60%+26.68%+49.35% 45.98B
-1.65%+0.44%+17.87%+124.17% 42.94B
-1.18%+1.48%+218.76%+828.43% 40.08B
-2.26%-2.06%+15.38%+45.14% 33.52B
+0.22%-4.77%+26.59%+0.55% 23.97B
+12.10%+16.60%+58.50%+46.15% 23.67B
Average +0.68%+2.06%+41.75%+139.16% 38.32B
Weighted average by Cap. +0.24%+2.59%+44.32%+151.11%

Financials

2026 *2027 *
Net sales - 1.67M 1.19M 1.06M 984K 891K 113M 1.69M 11.84M 4.68M 59.16M 4.46M 4.37M 187M
Net income -36.11M -25.75M -23.03M -21.31M -19.29M -2.45B -36.7M -256M -101M -1.28B -96.66M -94.59M -4.06B -37.94M -27.06M -24.2M -22.39M -20.27M -2.57B -38.56M -269M -107M -1.35B -102M -99.41M -4.26B
Net Debt -19.05M -13.59M -12.15M -11.24M -10.18M -1.29B -19.36M -135M -53.51M -676M -51M -49.91M -2.14B -6.59M -4.7M -4.21M -3.89M -3.52M -447M -6.7M -46.82M -18.52M -234M -17.65M -17.28M -741M
Projected Income Statement - Annual - Cardiol Therapeutics Inc.
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
27/10/26 CAD 1.590 0.00% 37,858
23/10/26 CAD 1.590 -3.05% 134,973
22/10/26 CAD 1.640 -1.20% 133,566
21/10/26 CAD 1.660 +1.84% 143,282
20/10/26 CAD 1.630 +3.82% 134,767
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cardiol Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.590CAD
Average target price
7.000CAD
Spread / Average Target
+340.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cardiol Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. CRDL Stock